Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EGFR-vIII CAR-T Cells |
| Synonyms | |
| Therapy Description |
EGFR-vIII CAR-T cells are T-cells that have been modified to express a chimeric antigen receptor (CAR) that targets EGFR variant III (EGFR-vIII), potentially leading to decreased growth of EGFR-vIII-expresing tumors (PMID: 28649003). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EGFR-vIII CAR-T Cells | EGFR-vIII CAR-T cells are T-cells that have been modified to express a chimeric antigen receptor (CAR) that targets EGFR variant III (EGFR-vIII), potentially leading to decreased growth of EGFR-vIII-expresing tumors (PMID: 28649003). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03283631 | Phase I | EGFR-vIII CAR-T Cells | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM | Terminated | USA | 0 |